Grants and Contributions:
Title:
ARP: Development of therapeutic antibodies targeting difficult membrane proteins involved in immune system modulation
Agreement Number:
1024406
Agreement Value:
$74,900.00
Agreement Date:
Nov 18, 2024 - Mar 31, 2025
Description:
The project aims to characterize and evaluate the therapeutic efficacy of bispecific antibodies targeting checkpoint inhibitors of the LILRB family as monotherapy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Sherbrooke, Quebec, CA J1E 0M8
Reference Number:
172-2024-2025-Q3-1024406
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
805852886
Recipient Type:
For-profit organization
Recipient's Legal Name:
Immune Biosolutions inc.
Federal Riding Name:
Sherbrooke
Federal Riding Number:
24073
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171